Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Simon, Thorsten ^a   Hero, Barbara ^a   Faldum, Andreas ^b   Handgretinger, Rupert ^c   Schrappe, Martin ^d   Klingebiel, Thomas ^e   Berthold, Frank ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CH14.18; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER STAGING; CAPILLARY LEAK SYNDROME; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRURITUS; SURVIVAL RATE; TREATMENT OUTCOME; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; DRUG THERAPY; FOLLOW UP; IMMUNOLOGY; IMMUNOTHERAPY; INFANT; METHODOLOGY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; OUTCOME ASSESSMENT; PRESCHOOL CHILD; REGRESSION ANALYSIS; RISK FACTOR; STEM CELL TRANSPLANTATION; TIME;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INFANT; MALE; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; OUTCOME ASSESSMENT (HEALTH CARE); REGRESSION ANALYSIS; RISK FACTORS; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 78651428141     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-21     Document Type: Article

References (21)

1. Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T, Spix C. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett 2003, 197(1-2):11-17. 10.1016/S0304-3835(03)00076-4, 12880954.
2. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008, 9(3):247-256. 10.1016/S1470-2045(08)70069-X, 18308250.
3. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999, 341(16):1165-1173. 10.1056/NEJM199910143411601, 10519894.
4. Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987, 5(9):1430-1440.
5. Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J, Reisfeld RA, Niethammer D. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 1992, 35(3):199-204. 10.1007/BF01756188, 1638557.
6. Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994, 12(1):184-193.
7. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingebiel T, Schrappe M, Reuland P, Gillies SD, Reisfeld RA, Neithammer D. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995, 31A(2):261-267. 10.1016/0959-8049(94)00413-Y, 7718335.
8. Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, Kung FH. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998, 16(6):2169-2180.
9. Cheung NK, Kushner BH, Yeh SD, Larson SM. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol 1998, 12(6):1299-1306.
10. Klingebiel T, Bader P, Bares R, Beck J, Hero B, Jurgens H, Lang P, Niethammer D, Rath B, Handgretinger R. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998, 34(9):1398-1402. 10.1016/S0959-8049(98)00130-0, 9849423.
11. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004, 22(17):3549-3557. 10.1200/JCO.2004.08.143, 15337804.
12. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Klin Padiatr 2005, 217(3):147-152. 10.1055/s-2005-836518, 15858706.
13. Brodeur GM, Prichard J, Berthold F, Carlsen NLT, Castel V, Castleberry RP, DeBernardo B, Evans AE, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993, 11(8):1466-1477.
14. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005, 6(9):649-658. 10.1016/S1470-2045(05)70291-6, 16129365.
15. Simon T, Hero B, Bongartz R, Schmidt M, Muller RP, Berthold F. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease. Strahlenther Onkol 2006, 182(7):389-394. 10.1007/s00066-006-1498-8, 16826357.
16. Collett D. Strategy for model selection. Modelling survival data in medical research 1994, 78-87. London: Chapman and Hall.
17. Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH, Seeger RC. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000, 18(24):4077-4085.
18. Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997, 80(2):317-333. 10.1002/(SICI)1097-0142(19970715)80:2<317::AID-CNCR21>3.0.CO;2-W, 9217046.
19. Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001, 19(22):4189-4194.
20. Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 2009, 27(1):85-91. 10.1200/JCO.2006.10.3564, 2645092, 19047298.
21. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010, 363(14):1324-1334. 10.1056/NEJMoa0911123, 20879881.